Related Experiment Video
Updated: Jul 20, 2026

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Histatin 5-derived peptide with improved fungicidal properties enhances human immunodeficiency virus type 1
Fedde Groot1, Rogier W Sanders, Olivier ter Brake
1Department of Human Retrovirology, Academic Medical Center, Meibergdreef 15, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Abstract:
Antimicrobial peptides are found in a number of body compartments and are secreted at mucosal surfaces, where they form part of the innate immune system. Many of these small peptides have a broad spectrum of inhibitory activity against bacteria, fungi, parasites, and viruses. Generally, the peptide's mode of action is binding and disruption of membranes due to its amphipathic properties. Histatin 5 is a salivary peptide that inhibits Candida albicans, an opportunistic fungus that causes oropharyngeal candidiasis in a majority of human immunodeficiency virus type 1 (HIV-1)-infected patients progressing towards AIDS. Previously, we increased the fungicidal properties of histatin 5 by replacing amino acids in the active domain of histatin 5 (Dh-5) (A. L. Ruissen, J. Groenink, E. J. Helmerhorst, E. Walgreen-Weterings, W. van't Hof, E. C. Veerman, and A. V. Nieuw Amerongen, Biochem. J. 356:361-368, 2001). In the current study, we tested the anti-HIV-1 activity of Dh-5 and its derivatives. Although Dh-5 inhibited HIV-1 replication, none of the peptide variants were more effective in this respect. In contrast, one of the derivatives, Dhvar2, significantly increased HIV-1 replication by promoting the envelope-mediated cell entry process. Most likely, Dhvar2 affects membranes, thereby facilitating fusion of viral and cellular membranes. This study shows that modification of antimicrobial peptides in order to improve their activity against a pathogen may have unpredictable and unwanted side effects on other pathogens.
Insights
Modifying antimicrobial peptides to enhance antifungal activity unexpectedly boosted human immunodeficiency virus type 1 (HIV-1) replication. This highlights potential risks of unintended consequences when altering innate immune peptides for therapeutic purposes.
Area of Science:
- Immunology
- Virology
- Biochemistry
Background:
- Antimicrobial peptides (AMPs) are crucial components of the innate immune system, protecting mucosal surfaces against pathogens.
- Histatin 5, a salivary AMP, inhibits Candida albicans, a fungus causing oropharyngeal candidiasis in HIV-1 patients.
- Previous research modified histatin 5's active domain, creating Dh-5 with enhanced fungicidal properties.
Purpose of the Study:
- To investigate the anti-HIV-1 activity of the modified peptide Dh-5 and its derivatives.
- To determine if modifications aimed at improving antifungal activity impact anti-HIV-1 efficacy.
- To assess potential unintended consequences of AMP modification on viral replication.
Main Methods:
- Testing Dh-5 and its derivatives for inhibition of HIV-1 replication in vitro.
- Evaluating the effect of peptide variants on HIV-1 envelope-mediated cell entry.
- Analyzing the mechanism by which peptides interact with viral and cellular membranes.
Main Results:
- Dh-5 demonstrated some inhibition of HIV-1 replication, but none of its derivatives showed improved anti-HIV-1 activity.
- One derivative, Dhvar2, significantly increased HIV-1 replication.
- Dhvar2's mechanism likely involves facilitating viral and cellular membrane fusion, enhancing viral entry.
Conclusions:
- Modification of AMPs can lead to unpredictable and detrimental side effects on other pathogens.
- Improving antifungal activity of histatin 5 did not translate to enhanced anti-HIV-1 effects and could be counterproductive.
- Careful consideration of off-target effects is necessary when developing modified AMPs for therapeutic use.
Related Concept Videos
Inhibitors of Virion Maturation and Assembly
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors

